GLOW Blend 70mg

GLOW Blend 70mg

GLOW combines GHK-Cu, BPC-157 and TB-500 in one peptide blend. GHK-Cu has been investigated for collagen production and tissue remodelling, while BPC-157 research includes tissue repair models. TB-500, a sythentic form of Thymosin Beta-4 is a natural protein found in the body that helps with tissue repair, reducing inflammation and improving flexibility.

Apply for a Trade Account

SEQUORA GLOW Blend 70mg is a three-compound Peptide blend containing 50mg GHK-Cu, 10mg BPC-157 and 10mg TB-500. Available in vial and prefilled pen formats, GLOW’s research explores processes involved in tissue repair and collagen production, including skin, tendon and intestinal research models.

Choose your product format
  • 70mg vial: an 80mg sealed vial of lyophilized powder (freeze dried). This format extends the shelf-life significantly and also allows freezer storage of your GLOW Blend. This vial can then be mixed with Bacteriostatic Water (BAC water) and be used as an injectable GLOW compound.
  • 80mg prefilled pen: A prepared reconstituted GLOW Blend in a 3ml cartridge. This is then inserted into a SEQUORA disposable injector pen for easy use and dosing.

The 70mg figure indicates the total stated content across all four compounds, not the concentration or amount delivered per withdrawal. Review the specifications for your selected format.

Purity & Verification

All of our products are third party laboratory tested to ensure both purity and verification of the peptide itself.

What is GLOW Blend 70mg used For?

SEQUORA GLOW Blend combines 50mg GHK-Cu, 10mg BPC-157 and 10mg TB-500 in a peptide blend. BPC-157 and thymosin-related peptide research shows to help with the bodies tissue repair process, while GHK-Cu is studied for collagen production and tissue remodelling.

What are the benefits of GLOW Blend 70mg?

GLOW by SEQUORA is known to boost skin vitality, aid with injury and tendon/ligament damage repair . It is used by both men and women for it’s longevity boosting benefits and body recovery.

Why buy GLOW Blend 70mg from SEQUORA?

SEQUORA’s GLOW blend is accurately dosed, providing 50mg of GHK-Cu, 10mg of BPC 157 and 10mg of TB-500 . We test all of our peptides for purity but also accurate dosing which can be found in the SEQUORA GLOW test summary.

Questions & Answers

What Is the GLOW Peptide Blend & Whats in it?

SEQUORA GLOW is a product name for an injectable blend of three peptides: GHK-Cu, BPC-157, and TB-500. The name GLOW is commonly used by most clinics and vendors for the same trio, and each ingredient is a separate compound with its own research history.

KLOW is GLOW plus KPV, which makes it a four-peptide blend. KPV is a short peptide that the FDA lists among substances nominated for compounding, and its regulatory story is covered in the status section below. The other three ingredients are identical in both products.

KPV’s main benefit is inflammation battling properties, so if this isn’t something you’re looking to treat or suffer with, then GLOW will have the same benefits as KLOW at a smaller price point.

Why are both GLOW and KLOW Blue in Colour?

GLOW’s characteristic blue colour comes from GHK-Cu, the copper peptide in the blend. GHK is a three-amino-acid peptide that binds to a copper ion. This complex absorbs certain wavelengths of visible light, giving it its blue appearance.

SEQUORA GLOW contains 50mg of GHK-Cu within its 70mg peptide blend, making it approximately 71% of the stated peptide content. BPC-157 and TB-500 do not normally contribute a blue colour.

The freeze-dried powder may appear pale blue, while a dissolved solution can look clear blue. Its appearance varies with concentration, formulation and lighting.

Side effects come from clinical trials and patient studies and are not confirmed medically. Injection site reactions are the most frequent as that’s a normal reaction to GHK-Cu and mild sensitivity or soreness around the injection site.

  • Anyone with a copper sensitivity or Wilson Disease should not use GLOW.
  • Anyone with active cancer or a recent cancer history should not use GLOW down to several of its components acting on blood vessel growth and cell migration.
  • ibuprofen, naproxen, and aspirin all conflict with the protocol, including the versions hiding inside cold and headache combination products.

Product Information Guide

GLOW

Product information, handling and safety

Storage

What Temperature should I store my GLOW at?

Safety

What are the best practices for using GLOW safely?

Evidence

The documentation behind GLOW and it's uses

What is GLOW?

GLOW combines GHK-Cu, BPC-157 and TB-500 in one peptide blend. GHK-Cu has been investigated for collagen production and tissue remodelling, while BPC-157 research includes tissue repair models. TB-500, a sythentic form of Thymosin Beta-4 is a natural protein found in the body that helps with tissue repair, reducing inflammation and improving flexibility.

Storage & Handling

Storage

Upon delivery store in a refridgerator between 2-8°C.

  • Avoid storing at the very back of the refridgerator.
  • Avoid exposure to heat, direct sunlight and temperature fluctuations.
  • Never freeze your SEQUORA GLOW Pens (Vials are safe to be frozen BEFORE reconstitution only).

Handling

Avoid dropping or heavy-handling of your GLOW Blend.

Please do not freeze your SEQUORA GLOW Pen as this can compromise the individual peptides.

Your product has been shipped in secure packaging to prevent any potential issues however if you believe your peptides have been compromised contact us directly.

shelf-life

Your SEQUORA GLOW Pen will last 12 months from the date of manufacture providing you follow the storage instructions provided.

SEQUORA GLOW Blend Vials before reconstitution can last up to 4 years at -5°C

GLOW can be kept at room temperature however it’s shelf life when held at this temperature reduces to 1-2 months.

Safety & Hygiene

pre-use hygiene

Before handling your GLOW, needles or injection material, ensure your research area is clean and clear.

Wash your hands with warm water and soap and allow to dry fully before handling any SEQUORA products to prevent cross contamination or infection risks.

If at any point the cleanliness of your injection or environment is compromised, restart this step.

needle & injection safety

Never re-use or share needles/syringes. Ensure your needle tips or syringe is sealed and new before injection.

Before using your SEQUORA GLOW Pen, using an alcohol swab, wipe the tip of the cartridge after removing the lid to the pen.

If at any point you touch something unhygienic or potentially dirty, re-wash your hands and use new equipment.

post-injection guidance

Ensure that your needle tips, syringes and vials are safely disposed of post-use.

This could mean a sharps bin or safe container. Most needle tips and syringes have removable tops that can be replaced onto the used needle.

Try to keep your injection site clean for atleast 30 minutes post-injection to prevent infection risks.

Potential GLOW Side Effects

GLOW combines GHK-Cu, BPC-157 and TB-500. Its safety profile as a combined injectable product has not been established. Human safety information for its ingredients is limited and individual user reports cannot reliably identify which ingredient caused a reaction.

Reported reactions and their limitations

  • Injection-site discomfort, redness or swelling have been reported with injectable peptide products, including reports involving BPC-157 and thymosin products.
  • Shortness of breath has been reported following injectable BPC-157 use, although the available report did not establish the cause.
  • Immune reactions are a potential concern with injectable peptide preparations, including reactions associated with impurities or peptide aggregation.

Individual user experiences

Online accounts involving GLOW and related blends describe injection-site stinging, burning, soreness or lumps. These are unverified personal reports, not established clinical side effects. Product identity, concentration, sterility and other substances used may be uncertain.

Other important risks and uncertainties

Combining GHK-Cu, BPC-157 and TB-500 introduces unanswered questions about compatibility, stability, interactions and long-term effects. Evidence about one ingredient does not establish the safety of the blend.

Injection introduces additional risks, including infection, abscess formation and tissue injury. Unexpected reactions may also relate to the diluent, contamination, incorrect concentration or administration technique.

When to seek medical advice

Stop use and seek prompt medical advice for persistent burning, worsening pain, a new rash or other unexplained symptoms. Increasing redness, warmth, swelling, discharge or fever requires prompt assessment for possible infection.

Symptoms requiring emergency help

Call 999 for difficulty breathing, sudden swelling of the lips, tongue or throat, chest pain or collapse. Do not assume breathing problems or a racing heartbeat are simply anxiety or a normal response to the product.

About this information

This summary distinguishes regulatory safety concerns, limited adverse-event reports and unverified personal experiences. These do not establish the frequency or cause of reactions to GLOW and are not verified adverse reactions to SEQUORA products. This information does not establish suitability for human use or replace medical advice.

GLOW Side Effect Mitigation

No mitigation protocol has been established that makes the GLOW blend safe. The following measures address reported injection-related problems and other potential risks. They are not a recommendation to continue using a product that causes symptoms.

Injection-site burning, soreness or lumps

  • Stop use if burning or pain is persistent, severe or worsening. Do not assume it indicates that the product is working.
  • Do not inject into skin that is already painful, inflamed, bruised or damaged.
  • Seek assessment for increasing redness, warmth, swelling, discharge or fever.
  • Do not attempt to correct irritation by adding more water, changing the solution’s pH or mixing in other substances without professional guidance.
  • Changing injection sites or allowing a solution to warm does not establish that a product causing reactions is safe to continue.

Rash or suspected allergic reactions

  • Stop use and seek medical advice for a new rash, itching or swelling.
  • Do not take another dose simply to test whether the reaction happens again.
  • Do not use antihistamines to mask symptoms so that administration can continue without assessment.
  • Call 999 for difficulty breathing or sudden swelling of the lips, tongue or throat.

Breathing discomfort, palpitations or feeling faint

Stop use and seek medical assessment. Do not manage these symptoms solely by changing the dose, dilution or timing. Call 999 for difficulty breathing, chest pain, collapse or palpitations accompanied by breathlessness or fainting.

Avoid unproven corrective measures

  • Do not assume symptoms are a detox reaction, a healing response or something that must be tolerated.
  • Do not start high-dose zinc, copper supplements or chelation treatments to counter suspected copper-related effects without medical assessment.
  • Do not assume cycling or taking breaks prevents copper-related harm. A safe cycling schedule for this injectable blend has not been established.
  • Avoid adding further research compounds to counter symptoms or improve tolerability.

Reduce contamination and preparation errors

  • Never share or reuse needles or syringes.
  • Do not use a vial with suspected contamination or damaged packaging. A clear appearance does not establish sterility.
  • Check that the diluent, final concentration and device specifications have been professionally verified.
  • Do not assume that removing KPV from another blend establishes the compatibility or stability of GLOW.

Keep a record of any reaction

  • Record the product name, batch details, stated concentration, amount used and time of administration.
  • Record when symptoms began and any other medicines, supplements or compounds taken.
  • Keep the packaging available and share these details with the healthcare professional assessing the reaction.

About this information

Personal reports can identify concerns worth investigating, but they cannot establish a safe dose or an effective mitigation strategy. These measures do not validate GLOW’s compatibility, stability, sterility or suitability for injection and do not replace individual medical advice.

Dosing Guidance For GLOW Blend 70mg

The GLOW Blend has a typical structure of 4-6 weeks “on-cycle” and 2-4 weeks “off-cycle”, this is mainly due to the copper accumulation from GHK-Cu.

GLOW Should be injected DAILY. Always confirm the pens strength before each administration.

Calculation basis: 70 mg total blend in a final volume of 3 ml, with 0.01 ml delivered per pen dial unit. “Dose” shows the nominal amount; “Total Dose” shows the calculated amount at the listed setting.

Dose Phase 70mg Pen Dial Setting Total Dose Breakdown of doses
1.75 mg Weeks 1–2 8 ≈1.867 mg total blend GHK-Cu: ≈1.333 mg / BPC-157: ≈267 mcg / TB-500: ≈267 mcg
3.5 mg Weeks 3–4 15 3.5 mg total blend GHK-Cu: 2.5 mg / BPC-157: 500 mcg / TB-500: 500 mcg
5.25 mg Weeks 5–8 23 ≈5.367 mg total blend GHK-Cu: ≈3.833 mg / BPC-157: ≈767 mcg / TB-500: ≈767 mcg
3.5 mg Weeks 9–12 (taper) 15 3.5 mg total blend GHK-Cu: 2.5 mg / BPC-157: 500 mcg / TB-500: 500 mcg

Understanding the figures

Doses are expressed in milligrams per daily administration. Each numbered dial of the pen delivers 0.01ml of liquid or 1 Unit. The SEQUORA 70mg GLOW Pen contains 3ml of reconstituted GLOW meaning every 1 dial = Approximately 0.2333 mg of GLOW Blend (166.7 mcg of GHK-Cu / 33.3 mcg each of BPC-157 and TB-500).